RCM-1-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemERCM-1Cat. No.: HY-19979CAS No.: 339163-65-4分式: CHNOS分量: 424.58作靶點(diǎn): Others作通路: Others儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 16.67 mg/mL (39.26 mM; Need ultrasonic)Mass Solvent1 mg 5

2、 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.3553 mL 11.7763 mL 23.5527 mL5 mM 0.4711 mL 2.3553 mL 4.7105 mL10 mM 0.2355 mL 1.1776 mL 2.3553 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 RCM-1FOXM1 的個(gè)抑制劑。IC50 & Target FOXM1 1.體外研究RCM-1 inhibits cellular proliferation via increasing dura

3、tion of cell cycle and mitosis in human and mousecancer cell lines in vitro. Treatment with RCM-1 increases duration of mitosis and cell cycle in the cancer celllines. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits1/2 Master of Small Molecules 您邊的

4、抑制劑師www.MedChemEmigration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as growthof cancer cell colonies in vitro 1.體內(nèi)研究 RCM-1 treatment reduces growth of Rd76-9 rhabdomyosarcomas in mice. RCM-1 treatment decreasestumor cell proliferation and increases ap

5、optosis in Rd76-9 rhabdomyosarcoma tumors. The RCM-1-treatedRd76-9 tumors show reduced FOXM1 staining and decreased expression of proliferation-specific markersKi67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase inapoptosis. RCM-1 treatment reduces

6、 growth of the B16-FlO melanoma tumors in mice. RCM-1 decreasesthe B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumorcell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces growth ofthe human H2122 lung adenocarcino

7、ma in mice 1.PROTOCOLCell Assay 1 Rd76-9 rhabdomyosarcoma, B16-FlO melanoma, H2122 lung adenocarcinoma, 4T1 breast carcinoma, MyC-CaP prostate carcinoma and KPC-2 pancreatic carcinoma cells are seeded in 6-well plates and incubatedovernight. The cells are treated with 20 M concentration of RCM-1 for

8、 24, 48 and 72 h and cell growth isanalyzed by counting alive cells using trypan blue. Cells treated with DMSO are used as controls 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Mouse Rd76-9 rhabdomyosarcoma cells (1106

9、 cells) are injected intramuscularly in the flanks of C56Bl/6Jmice (n=8 mice per group). Seven days after the tumor cells inoculation, 40 L of either Vehicle (DMSO) orRCM-1 (20 mg/kg body weight) are injected intraperitoneally in the animals every other day. The animals aresacrificed and tumors are

10、harvested on day 16. RCM-1 treatment decreases Rd76-9 tumor growth ascompared to the DMSO-treated group. Mouse B 16-FlO melanoma cells (1106 cells) are injectedsubcutaneously in C56Bl/6J mice (n=7 animals per group). Three days after the tumor cell inoculation, 40 Lof either Vehicle (DMSO) or RCM1 (

11、20 mg/Kg body weight) are injected intraperitoneally in the animals everyother day. The animals are sacrificed and tumors are harvested on day 12 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. ARYL SULFONOHYDRAZIDES.WO2018057550A1.McePdfHeightCaution: Product has not